Cargando…

NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	Zhang, Yun, Dong, Zhifang, Song, Weihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109024/ https://www.ncbi.nlm.nih.gov/pubmed/32296063 http://dx.doi.org/10.1038/s41392-020-0145-7

Ejemplares similares

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

NLRP3 Inflammasome as Therapeutic Targets in Inflammatory Diseases
por: Prakash, Annamneedi Venkata, et al.
Publicado: (2023)

EphB2: potential therapeutic target for Alzheimer’s disease
Publicado: (2011)

NLRP3 inflammasome as a novel therapeutic target for heart failure
por: Wang, Shuangcui, et al.
Publicado: (2021)

Microglial lactate metabolism as a potential therapeutic target for Alzheimer’s disease
por: Zhao, Yingjun, et al.
Publicado: (2022)

Activation of NLRP3 Inflammasome and Onset of Alzheimer’s Disease
por: Bai, Hua, et al.
Publicado: (2021)

The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
por: Fan, Jiwen, et al.
Publicado: (2022)

Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis
por: Cai, Yawen, et al.
Publicado: (2022)

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
por: Merino‐Vico, Ana, et al.
Publicado: (2022)

The inflammasome: Friend or foe in Chlamydia infection?
por: Walton, Emma Louise
Publicado: (2016)

A novel strategy for bioactive natural products targeting NLRP3 inflammasome in Alzheimer’s disease
por: Yang, Zhiyou, et al.
Publicado: (2023)

The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease
por: Hanslik, Kendra L., et al.
Publicado: (2020)

A novel “complement–metabolism–inflammasome axis” as a key regulator of immune cell effector function
por: Arbore, Giuseppina, et al.
Publicado: (2016)

Alzheimer’s disease: targeting the peripheral circulation
por: Liu, Zhi-Hao, et al.
Publicado: (2023)

He protec but he also attac – Inflammasomes swinging the sword()
por: Kattner, Aila Akosua
Publicado: (2023)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
por: Chen, Ruixiang, et al.
Publicado: (2021)

Targeting microglial autophagic degradation of the NLRP3 inflammasome for identification of thonningianin A in Alzheimer’s disease
por: Zhou, Xiao-Gang, et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations
por: Nguyen, Linh Thi Nhat, et al.
Publicado: (2022)

The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets
por: Bai, Rongrong, et al.
Publicado: (2021)

NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease
por: Zhuang, Dian, et al.
Publicado: (2023)

Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
por: Lu, Ranran, et al.
Publicado: (2022)

Chronic kidney disease and NLRP3 inflammasome: Pathogenesis, development and targeted therapeutic strategies
por: Huang, Gengzhen, et al.
Publicado: (2022)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

NLRP3 inflammasome: a new therapeutic target for high-risk reproductive disorders?
por: Zhou, Feng, et al.
Publicado: (2021)

Mitochondrial dysfunction and alcohol-associated liver disease: a novel pathway and therapeutic target
por: Abdallah, Mohamed A., et al.
Publicado: (2020)

Targeting the NLRP3 Inflammasome in Glaucoma
por: Coyle, Sophie, et al.
Publicado: (2021)

Tainted air: The link between pollution and Alzheimer's disease
por: Walton, Emma Louise
Publicado: (2018)

For better or worse: Immune system involvement in Alzheimer's Disease
por: Walton, Emma L.
Publicado: (2018)

Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2021)

Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer
por: Tezcan, Gulcin, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in Lupus Nephritis and Therapeutic Targeting by Phytochemicals
por: Wu, Dantong, et al.
Publicado: (2021)

Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2023)

Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer
por: Wang, Xixi, et al.
Publicado: (2023)

Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases
por: Shao, Bo-Zong, et al.
Publicado: (2018)

Role of the NLRP3 inflammasome in neurodegenerative diseases and therapeutic implications
por: Duan, Yanhui, et al.
Publicado: (2020)

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
por: Seok, Jin Kyung, et al.
Publicado: (2021)

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity?
por: Merighi, Stefania, et al.
Publicado: (2022)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o0dhqmv5q2ai5iofu7miefg4vc